Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) - Share price - Overview

Stock Report

Alnylam Pharmaceuticals Inc ALNY

Last Price
$69.50

Day Change
-0.47|-0.67%

As of 25/05/2017
16:32:19 EDT | USD
Minimum 15 Minutes Delay.

Last Close69.97
Day Range69.29 - 70.98
Mkt Cap5.99Bil
52-Wk Range31.38 - 80.11
Yield %-
ISINUS02043Q1076
Volume1,010,113
P/E-14.39
P/S101.01
P/CF-18.38

Share Price

Financials
201420152016
More ...
Income Statement
Revenue50.5641.1047.16
Operating Income-404.98-296.01-424.59
Net Income-360.40-290.07-410.11
Basic EPS-4.85-3.45-4.79
Avg. Diluted Shares Outstanding748486
Balance Sheet
Current Assets746.371,105.39671.88
Non Current Assets333.23281.12590.93
Total Assets1,079.601,386.511,262.81
Current Liabilities95.3362.10131.70
Total Liabilities143.33121.80342.59
Total Equity936.271,264.71920.22
Cash Flow
Operating Cash Flow-165.64-189.14-307.70
Capital Expenditure-33.96-12.95-64.56
Free Cash Flow-199.60-202.09-372.26

In millions, except "Basic EPS". Currency is USD.

Company Profile

Alnylam Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in developing novel therapeutics based on RNA interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for regulating the expression of specific genes.

Sector

Healthcare

Industry

Biotechnology

Stock Style

Mid-Growth

Fiscal Year Ends

December

Employees

514
Key Stats
More ...
Price/Earning TTM-14.49
Price/Book7.26
Price/Sales TTM127.01
Rev Growth (3 year avg)-0.01
EPS Growth (3 year avg)-
Operating Margin % TTM-900.33
Net Margin % TTM-869.63
ROE TTM-37.54
Debt/Equity0.16
Dividends
PreviousLatest
More ...
Declared Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00
AJ Bell includes AJ Bell Holdings Limited and its wholly owned subsidiaries. AJ Bell Management Limited and AJ Bell Securities Limited are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2017 Morningstar. All rights reserved.